NEW YORK & TOKYO - Pfizer Inc. (NYSE: NYSE:PFE) and Astellas Pharma Inc. (TSE: TYO:4503) have announced updated results from the Phase 3 EV-302 clinical trial, which showed that the combination of ...
TC BioPharm (NASDAQ: TCBP) has completed full dosing for the first Cohort B patient in its Phase 2B ACHIEVE clinical trial evaluating TCB008 for acut ...
Cohort B recruitment continues at multiple clinical sites across the United Kingdom EDINBURGH, Scotland, Feb. 10, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") ...
PLC (NASDAQ: TCBP), a biotechnology firm with a market capitalization of $33.08 million engaged in developing gamma-delta T cell therapies, announced today significant progress in its ACHIEVE Phase 2B ...
PLC (NASDAQ: TCBP) shares lost some ground Monday, as the Edinburgh-based clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other ...
Orca Bio to present efficacy and safety data with Orca-T compared to conventional allogeneic hematopoietic stem cell transplant (alloHSCT) at the 51st Annual ...
TC BioPharm (TCBP) announced the first Cohort B patient in the ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 in Acute Myeloid Leukemia, ...
PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...
Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback